JPRN-UMIN000035616招募中未知
Prospective observational study of anti-PD-L1 antibody drug atezolizumab for non small cell lung cancer - Prospective study of atezolizumab
Second division, Depertment of Internal Medicine, Hamamatsu University School of Medicine0 个研究点目标入组 100 人开始时间: 2019年1月28日最近更新:
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1. Patients with autoimmune diseases or recurrent autoimmune disease 2. Patient with interstitial pneumonia 3. Patients with serious complications 4. Patients with difficult-to-control central nervous lesions
研究者
相似试验
已完成
不适用
Prospective pilot study of anti-PD-L1 antibody therapy in advanced non-small cell lung cancer patients who previously responded to anti-PD-1 antibodyadvanced non-small cell lung cancerJPRN-UMIN000031888Saitama medical university International medical Center20
招募中
不适用
Prospective study of anti-PD-L1 antibody therapy in advanced non-small cell lung cancer patients who previously treated with anti-PD-1 antibodylung cancerJPRN-UMIN000033288Japanese Red Cross Medical Center30
进行中（未招募）
1 期
udwigEUCTR2015-005298-19-GBudwig Institute for Cancer Research Ltd.75
招募中
2 期
A phase II open-label study with the anti-PD-L1 Atezolizumab monoclonal antibody in combination with Bevacizumab in patients with advanced chemotherapy resistant colorectal cancer and MSI-like molecular signaturebowlecancercolorectal carcinoma10017991NL-OMON49178Vall D'Hebron Institute of Oncology (VHIO)12
进行中（未招募）
1 期
Atezolizumab in combination with Beva in advanced CRC with MSI-like molecular signatureColorectal carcinomaMedDRA version: 20.0Level: PTClassification code 10061451Term: Colorectal cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2016-002001-19-ESVHIO58